


STEREOSPECIFIC SYNTHESIS OF AN  $\alpha$ -MANNOSIDASE  
INHIBITOR RELATED TO SWAINSONINE

Philip DeShong\*, Daniel R. Sidler, David A. Kell, and Nathan N. Aronson, Jr.  
Departments of Chemistry and Molecular and Cell Biology  
The Pennsylvania State University  
University Park, PA 16802

**Abstract** A stereospecific synthesis of pyrrolidine 2, an analog of swainsonine and an inhibitor of lysosomal  $\alpha$ -D-mannosidase, is described.


Swainsonine (1), the neurotoxic indolizidine alkaloid found in locoweed<sup>1</sup> is a potent inhibitor of lysosomal and jack bean  $\alpha$ -D-mannosidase and Golgi mannosidase II.<sup>2,3</sup> Administration of the alkaloid to animals affects processing of glycoproteins in the liver and results in formation of hybrid rather than complex glycoproteins.<sup>4</sup>

As part of our project to elucidate the mechanism of action of glycosidase enzymes<sup>5</sup>, we have developed a stereospecific synthesis of pyrrolidine 2 and investigated its activity in lysosomal preparations.



Heating a benzene solution of aziridine 3 and vinylene carbonate (5) at 165°C for 72 hours gave pyrrolidine carbonate 6<sup>6</sup> as the only cycloadduct in 65% yield. This reaction presumably proceeds by [3+2] dipolar cycloaddition of azomethine ylid 4 and 5.<sup>7</sup> Simultaneous reduction of the carbonate and ester moieties with LiAlH<sub>4</sub> gave triol 2 (50%).<sup>8</sup> Using this procedure, it is possible to secure multigram quantities of 2 from readily available materials.

Preliminary studies have shown that racemic pyrrolidine 2 specifically inhibits the  $\alpha$ -D-mannosidase activity in an extract of purified liver lysosomes.<sup>9</sup> At a concentration of 8mM, pyrrolidine 2 produced 50% inhibition of the mannosidase activity<sup>10</sup> while the activities of  $\beta$ -D-mannosidase,  $\beta$ -D-galactosidase, N-acetyl- $\beta$ -D-glucosaminidase and  $\alpha$ -L-fucosidase were unaffected.



**Acknowledgement.** We thank the National Institutes of Health (AM 33314) for generous financial support.

#### Reference and Notes.

1. Colegate, S. M.; Dorling, P. R.; Huxtable, C. R. *Aust. J. Chem.* **1979**, *32*, 2257. Molyneux, R. J.; James, L. F. *Science* **1982**, *216*, 190. Schneider, M. J.; Ungemach, F. S.; Broquist, H. P.; Harris, T. M. *Tetrahedron* **1983**, *39*, 29. (-)-Swainsonine has been synthesized previously: Ali, M. H.; Hough, L.; Richardson, A. C. *J. Chem. Soc., Chem. Commun.* **1984**, 447. Yasuda, N.; Tsutsumi, H.; Takaya, T. *Chemistry Lett.* **1984**, 1201. Fleet, G. W. J.; Gough, M. J.; Smith, P. W. *Tetrahedron Lett.* **1984**, *25*, 1853. Adams, C. E.; Walker, F. J.; Sharpless, K. B. *J. Org. Chem.* **1985**, *50*, 420. Fleet has reported the total synthesis of an analog of swainsonine: Fleet, G. W. J.; Smith, P. W.; Evans, S. V.; Fellows, L. E. *J. Chem. Soc., Chem. Commun.* **1984**, 1240.
2. Tulsiani, D. R. P.; Broquist, H. P.; Touster, O. *Arch. Biochem. Biophys.* **1985**, *236*, 427, and references cited therein.
3. Tulsiani, D. R. P.; Harris, T. M.; Touster, O. *J. Biol. Chem.* **1982**, *257*, 7936.
4. Tulsiani, D. R. P.; Touster, O. *J. Biol. Chem.* **1983**, *258*, 7578. Gross, V.; Tran-Thi, T.-A.; Vosbeck, K.; Heinrich, P. A. *J. Biol. Chem.* **1983**, *258*, 4032. Kang, M. S.; Elbein, A. D. *J. Virol.* **1983**, *46*, 60. Arumugham, R. G.; Tanzer, M. L. *J. Biol. Chem.* **1983**, *258*, 11883.
5. Nojirimycin, deoxynojirimycin, castanospermine, and 1,5-dideoxy-1,5-imino-5-mannitol have also been shown to be specific inhibitors of various glycosidase enzymes.
6. Pyrrolidine **6**: m.p. 140-1°C; IR(KBr)1815(s), 1730(s)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$ (acetone- $d_6$ )  $\delta$ 6.77(m, 4H), 5.68(t,  $J=7.0$ , 1H), 5.50(ddd,  $J=7.0, 5.0, 1.0$ , 1H), 4.45(d,  $J=7.0$ , 1H), 4.00(dd,  $J=11.5, 1.0$ , 1H), 3.71(s, 6H), 3.50(dd,  $J=11.5, 5.0, 1.0$ , 1H); mass spectrum,  $m/z$  (rel. int.) 293(22), 234(100). Anal. Calcd. for  $\text{C}_{14}\text{H}_{15}\text{NO}_6$ : C, 57.34; H, 5.16; N, 4.78. Found: C, 57.42; H, 5.21; N, 4.75.
7. For additional examples of azomethine ylid cycloadditions see DeShong, P.; Kell, D. A.; Sidler, D. R. *J. Org. Chem.* **1985**, *50*, in press, and references cited therein.
8. Triol **2**: m.p. 126-7°C; IR(KBr)3400-3150(BR);  $^1\text{H NMR}$ (acetone- $d_6$ )  $\delta$ 6.70(m, 4H), 4.40(m, 1H), 3.97(m, 2H), 3.77(m, 2H), 3.68(s, 3H), 3.40(dd,  $J=10.5, 1.0$ , 1H), 3.29(dd,  $J=10.5, 4.5$ , 1H), 2.92(s, 3H); mass spectrum,  $m/z$  (rel. int.) 239(14), 208(100).
9. Aronson, N. N., Jr.; deDuve, C. *J. Biol. Chem.* **1968**, *243*, 4564.
10.  $\text{IC}_{50}$  for swainsonine is  $8\mu\text{M}$ . Further results in the inhibition of  $\alpha$ -D-mannosidase systems by swainsonine analog **2** and related substances will be reported elsewhere.

(Received in USA 22 April 1985)